



## **Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit**

October 20, 2021

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- [Beam Therapeutics Inc.](#) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 4:00 p.m. ET.

The live webcast will be available in the investor section of the company's website at [www.beamtx.com](http://www.beamtx.com). The webcast will be archived for 60 days following the presentation.

### **About Beam Therapeutics**

Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

### **Contacts:**

#### Investors:

Chelcie Lister

THRUST Strategic Communications

[chelcie@thrustsc.com](mailto:chelcie@thrustsc.com)

#### Media:

Dan Budwick

1AB

[dan@1abmedia.com](mailto:dan@1abmedia.com)